Similarly, SJF-0628 results in the degradation of BRAF-mutant cancers in a dose-dependent manner within four hours with no ERK phosphorylation for up to 72 h and only 30% recovery of BRAF activity after washout within 24 h, highlighting the extended catalytic activity of BRAF-PROTAC treatment [110]. The gene discussed is MAPK1; the disease is cancer.